Fairtree Asset Management Pty Ltd Acquires New Holdings in Smith & Nephew SNATS, Inc. $SNN

Fairtree Asset Management Pty Ltd bought a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 29,539 shares of the medical equipment provider’s stock, valued at approximately $1,853,000.

Several other large investors have also recently bought and sold shares of SNN. Equity Investment Corp increased its stake in Smith & Nephew SNATS by 3.9% in the 4th quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock worth $246,000 after acquiring an additional 285 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Smith & Nephew SNATS by 13.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 334 shares in the last quarter. Cary Street Partners Financial LLC lifted its position in Smith & Nephew SNATS by 1.8% during the fourth quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock valued at $665,000 after purchasing an additional 365 shares during the last quarter. Parallel Advisors LLC lifted its position in Smith & Nephew SNATS by 20.0% during the first quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after purchasing an additional 387 shares during the last quarter. Finally, Clearstead Trust LLC purchased a new position in Smith & Nephew SNATS in the 2nd quarter worth approximately $25,000. 25.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SNN has been the topic of several research reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew SNATS in a research report on Thursday, August 6th. Wall Street Zen cut Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Sunday, August 16th. Zacks Research cut Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a report on Friday, August 7th. Weiss Ratings lowered Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, June 11th. Finally, Kepler Capital Markets cut Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Two analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Smith & Nephew SNATS has an average rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Price Performance

Shares of NYSE:SNN opened at $29.06 on Friday. The stock’s 50-day moving average price is $30.35 and its 200-day moving average price is $31.89. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS, Inc. has a 12-month low of $28.56 and a 12-month high of $38.79.

Smith & Nephew SNATS Dividend Announcement

The business also recently declared a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be paid a $0.312 dividend. This represents a yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.